RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) yesterday and set a price target of $125.00. The company’s shares closed ...

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.31 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $2.20 per share a year ago.

Adjusted Tax Rate: 17.5% for the fourth quarter of 2024. Zimmer Biomet Holdings Inc (NYSE:ZBH) reported nearly 5% constant currency sales growth in Q4 2024, marking the 12th consecutive quarter of mid ...

Zimmer Biomet Holdings Inc is a global leader in medical technology, specializing in designing and manufacturing orthopedic reconstructive products, including knee and hip replacements. Beyond ...

Zimmer Biomet Holdings, Inc. ZBH posted fourth-quarter 2024 adjusted earnings per share (EPS) of $2.31, beating the Zacks Consensus Estimate by a penny. The adjusted figure increased 5% year over ...

Despite reporting better-than-expected Q4 2024 results, shares of Zimmer Biomet (NYSE:ZBH) fell in the morning hours Thursday after the orthopedic device maker set its 2025 outlook below consensus.

Zimmer Biomet posted Q4 adjusted EPS of $2.31, surpassing estimates, with sales of $2.02B, driven by strong knee and hip product growth. The company expects FY25 adjusted EPS of $8.15-$8.35 ...

On Thursday, Zimmer Biomet Holdings, Inc (NYSE:ZBH) reported fourth-quarter adjusted EPS of $2.31, up from $2.20 a year ago, beating the Street estimates of $2.30. The orthopedic giant reported ...

Zimmer Biomet (NYSE: ZBH) + shares dipped slightly today on fourth-quarter results that came in just ahead of the consensus forecast on Wall Street. Shares of ZBH fell 1.6% to $106.50 apiece in ...